Traditional Chinese medicine composition for treating primary immune thrombocytopenia

Abstract

The invention discloses a traditional Chinese medicine composition for treating primary immune thrombocytopenia. Active ingredients of the traditional Chinese medicine composition are prepared from the following crude drugs in parts by weight: 50-70 parts of hairyvein agrimonia herbs, 5-15 parts of platycodon roots, 5-15 parts of smoked plums, 5-15 parts of common aucklandia roots, 10-30 parts ofprepared radix glycyrrhizae,10-30 pats of parched white atractylodes rhizomes, 10-30 parts of debark peony roots, 10- 30 parts of areca seeds, 20-40 parts of fried coix seeds, 20-40 parts of poria cocos, 20-40 parts of atrina glass, 20-40 parts of milkvetch roots, 20-40 parts of codonopsis pilosula, 5-15 parts of tortoise-plastron glues and 5-15 parts of largetrifoliolious bugbane rhizomes. The invention has effects in stopping bleeding, increasing platelets and regulating immunity, and is fast in taking effect, exact in curative effect, not easy to relapse and free of toxic side effects. After clinical practice, the traditional Chinese medicine composition shows a cure rate as high as 98%, and the traditional Chinese medicine composition is the choice drug for treating the primary immunethrombocytopenia.

Description

Technical field: [0001] The invention relates to a traditional Chinese medicine for idiopathic thrombocytopenic purpura, in particular to a traditional Chinese medicine composition for treating idiopathic thrombocytopenia. Background technique: [0002] Essential thrombocytopenia, also called idiopathic thrombocytopenic purpura, is an immune syndrome and a common bleeding disorder. It is characterized by the presence of anti-platelet antibodies in the blood circulation, causing excessive damage to platelets and causing purpura; while the megakaryocytes in the bone marrow are normal or increased, and naive; clinically, it can be divided into acute and chronic. [0003] Thrombocytopenia can be roughly divided into three situations: a. The first is the disorder of platelet production itself. For example, aplastic anemia, leukemia, or myelofibrosis occurs in the bone marrow; b. The second is excessive consumption. For example, the use of chemotherapy drugs, or exposure to radia...

AI Technical Summary

Problems solved by technology

[0004] Now the treatment of thrombocytopenic purpura generally adopts hormone therapy and blood transfusion as the main method, but once the delivery of hormones stops, the disease will start to attack again; and the side effects of long-term delivery of hormones are relatively large, and there will be complications and transfer after a long time lesions, and high cost of treatment